Article: Intrexon Follows RheoGene Merger With $25M Series C1.

Staff Writer

Preclinical gene therapy company Intrexon Corp. pulled down $25 million in a Series C1 round backed entirely by venture capital firm Third Security LLC.

The financing brings the total private equity investment in Blacksburg, Va.-based Intrexon to $32.3 million, most of it provided through funds managed by Radford, Va.-based Third Security.

Intrexon CEO Robert Beech said the funds will support the company's efforts to advance its lead gene therapy program for melanoma into clinical trials by the end of the year, pending regulatory approvals. A program in glioma is "not far behind," he said, adding that Intrexon is interesting in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!